INFINITI
2 years ago
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium
Source: PR Newswire (US)
SBT-272 improved neuronal health, superior to other approved and investigational agents
Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway
BOSTON, June 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology, which plays a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium in Keystone, CO held June 5-9, 2022. A Phase 1 study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.
Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics)
SBT-272 significantly improved mitochondrial structural integrity and motility in TDP-43 mutant (A315T)-expressing upper motor neurons. These enhancements in mitochondrial health were associated with improved axon outgrowth, a key indicator of improved neuronal health. The effect of SBT-272 on axon outgrowth was superior to edaravone (approved for the treatment of ALS) and AMX0035 (NDA under FDA review). Chronic in vivo administration of SBT-272 reduced upper motor neuron degeneration and neuroinflammation in the motor cortex of the prp-hTDP-43A315T-UeGFP mouse model of ALS. Together, these data support further investigation of SBT-272 as a potential treatment for ALS with TDP-43 pathology.
"Upper motor neuron degeneration is an early event in ALS, which is characterized by degeneration of both the upper motor neurons in the brain and the lower motor neurons in the spinal cord," said Hande Ozdinler, PhD, Associate Professor of Neurology, Feinberg School of Medicine, Northwestern University. "Therefore, to build effective treatment strategies for ALS, it is necessary for therapeutics to demonstrate efficacy on upper motor neuron health and function. The new findings presented today further strengthen the importance of improving mitochondrial health with respect to TDP-43 pathology in ALS and lay a strong foundation for the clinical development of SBT-272 for ALS patients."
"ALS is a devastating progressive neuromuscular disease with a significant unmet medical need," said Reenie McCarthy, Chief Executive Officer of Stealth BioTherapeutics. "We designed SBT-272 to target mitochondrial dysfunction in the brain, which is known to precede and contribute to several neurodegenerative diseases, including ALS. We are encouraged that Dr. Ozdinler's team has elucidated these signals of neuronal protection, and we look forward to working with the ALS community to progress the clinical development of SBT-272."
About SBT-272
SBT-272 is a novel small molecule that targets the cardiolipin-rich inner mitochondrial membrane which is crucial for normal mitochondrial structure and function. Preclinical SBT-272 data have demonstrated mitochondria-protective and neuroprotective effects in models of ALS, FTD, alpha-synucleinopathy, a rare form of dementia that is similar to Parkinson's disease, Huntington's disease and ischemic stroke. We have also observed SBT-272-mediated improvements in functional assessments, lifespan, inflammation, and reduction of protein aggregates across certain nonclinical models. A Phase 1 study evaluating subcutaneous SBT-272 in healthy volunteers is ongoing. We aim to develop SBT-272 for ALS and other neurological diseases of mitochondrial dysfunction.
About Stealth BioTherapeutics
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. We believe our lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD, rare neuromuscular disorders, such as primary mitochondrial myopathy and Duchenne muscular dystrophy, and rare cardiomyopathies, such as Barth syndrome. We are evaluating our second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications, such as amyotrophic lateral sclerosis and frontotemporal lobar dementia, following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Stealth BioTherapeutics' expectations for SBT-272 preclinical data and Phase 1 clinical development efforts. Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics' ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics' product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics' product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics' product candidates; the content and timing of decisions made by the FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics product candidates; Stealth BioTherapeutics' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Stealth BioTherapeutics' most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as in any future filings with the SEC. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Investor Relations
Kendall Investor Relations
Adam Bero, Ph.D.
abero@kendallir.com
IR@StealthBT.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-presents-new-sbt-272-data-demonstrating-improvement-in-upper-motor-neuron-function-in-als-disease-model-at-keystone-neurodegeneration-symposium-301563589.html
SOURCE Stealth BioTherapeutics Inc.
conix
2 years ago
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2
Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022
Mon, May 23, 2022
New analysis demonstrates correlation between ellipsoid zone dysfunction and vision
BOSTON, May 23, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced new data from the ReCLAIM-2 study of elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) at the Clinical Trials at the Summit meeting in Lake Tahoe, Nevada.
Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics)
Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics)
The ReCLAIM-2 prespecified analyses demonstrate that elamipretide ameliorated progressive decline, or attenuation, of the mitochondrial rich ellipsoid zone (EZ) layer of the photoreceptors (p<0.01) and showed a categorical >2-line improvement in low luminance visual acuity (LLVA) (p=0.04) in patients with GA. Progressive LLVA dysfunction, which is among the first symptoms of dry AMD, compromises patients' ability to see under low-light conditions such as at dusk, in the evening, or indoors using artificial light. Additional analyses show that, consistent with prior findings from the ReCLAIM Phase 1 study, changes in LLVA correlated with baseline EZ attenuation in ReCLAIM-2. The new analyses also show that elamipretide-mediated reduction of progressive EZ attenuation correlated with improvements in LLVA. Although the trial's primary endpoints of mean change in LLVA and GA progression were not met, these analyses were found to be promising and to support and inform the continued development of elamipretide for dry AMD.
Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to progressive loss of vision. One of the earliest signs of photoreceptor dysfunction is progressive damage to, or attenuation of, the ellipsoid zone (EZ), which is a mitochondrial rich layer of the photoreceptors. EZ attenuation has been shown to precede and predict visual dysfunction in dry AMD and other retinal diseases.
"Preserving the health of structures in the eye needed for visual function, such as photoreceptors, is critical for patients with dry AMD," said Jeffrey Heier, M.D., the principal investigator of the ReCLAIM-2 study and director, retina service, and director, retinal research, Ophthalmic Consultants of Boston. "I am pleased to present these data underscoring for the first time the important relationship between mitochondrial health and vision in GA, which we hope will inform future efforts to improve outcomes for patients living with this progressive and irreversible disease."
Elamipretide was generally well tolerated in ReCLAIM-2. The rate of new-onset exudations was 5.3% in the elamipretide treated group versus 6.9% in placebo.
"We are excited to confirm that targeting mitochondrial dysfunction in dry AMD may preserve and potentially improve visual function for some affected patients," said Reenie McCarthy, CEO of Stealth BioTherapeutics. "We believe these data can help enrich and inform future development efforts for this devastating disease, and we are evaluating strategies to progress this program, including through potential partnering discussions."
The company is also progressing the clinical development of elamipretide in several rare disease indications as well as advancing a broad pipeline of novel mitochondria-targeting compounds.
About Dry AMD
Dry AMD is a leading cause of blindness impacting more than 5 million people worldwide which can severely impair visual function, independence, and quality of life.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. We believe our lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD, rare neuromuscular disorders, such as primary mitochondrial myopathy and Duchenne muscular dystrophy, and rare cardiomyopathies, such as Barth syndrome. We are evaluating our second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications, such as amyotrophic lateral sclerosis and frontotemporal dementia, following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
THEMASTERS_SON
2 years ago
trendzone
2 years ago
PStockPickz
2 years ago
KeepOn
2 years ago
boston127
3 years ago
ClayTrader
3 years ago
Surfacetite
3 years ago
TheFinalCD
3 years ago
Hot Features
Premium
